Akero Therapeutics Stock Today

AKRO Stock  USD 25.68  0.84  3.38%   

Performance

6 of 100

 
Weak
 
Strong
Modest

Odds Of Distress

Less than 8

 
High
 
Low
Low
Akero Therapeutics is selling at 25.68 as of the 14th of July 2024; that is 3.38 percent increase since the beginning of the trading day. The stock's open price was 24.84. Akero Therapeutics has only a 8 % chance of going through financial distress over the next few years but had a somewhat modest performance during the last 90 days. Equity ratings for Akero Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of June 2024 and ending today, the 14th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
20th of June 2019
Category
Healthcare
Classification
Health Care
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. The company has 69.15 M outstanding shares of which 6.47 M shares are presently shorted by private and institutional investors with about 6.27 trading days to cover. More on Akero Therapeutics

Moving against Akero Stock

  0.69VTYX Ventyx BiosciencesPairCorr
  0.52WAT WatersPairCorr
  0.45HCM HUTCHMED DRCPairCorr
  0.44EVGN EvogenePairCorr
  0.41VALN Valneva SE ADRPairCorr
  0.31IKT Inhibikase TherapeuticsPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Akero Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentAndrew MD
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities13.9 M19.1 M
Way Down
Slightly volatile
Non Current Liabilities Total19.4 M25.8 M
Way Down
Pretty Stable
Total Assets609.3 M580.3 M
Sufficiently Up
Slightly volatile
Total Current Assets588 M560 M
Sufficiently Up
Slightly volatile
Debt Levels
Akero Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Akero Therapeutics' financial leverage. It provides some insight into what part of Akero Therapeutics' total assets is financed by creditors.
Liquidity
Akero Therapeutics currently holds 26.04 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Akero Therapeutics has a current ratio of 6.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Akero Therapeutics' use of debt, we should always consider it together with its cash and equity.

Begin Period Cash Flow

262.26 Million
Akero Therapeutics (AKRO) is traded on NASDAQ Exchange in USA. It is located in 601 Gateway Boulevard, South San Francisco, CA, United States, 94080 and employs 58 people. Akero Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.78 B. Akero Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 69.15 M outstanding shares of which 6.47 M shares are presently shorted by private and institutional investors with about 6.27 trading days to cover. Akero Therapeutics currently holds about 180.72 M in cash with (145.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.81.
Check Akero Therapeutics Probability Of Bankruptcy
Ownership Allocation
The majority of Akero Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Akero Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Akero Therapeutics. Please pay attention to any change in the institutional holdings of Akero Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Akero Ownership Details

Akero Stock Institutional Holders

InstituionRecorded OnShares
Boxer Capital Llc2024-03-31
1.7 M
Alliancebernstein L.p.2024-03-31
1.6 M
Yiheng Capital Llc2024-03-31
1.4 M
Geode Capital Management, Llc2024-03-31
1.4 M
Perceptive Advisors Llc2024-03-31
1.4 M
Fred Alger Management, Llc2024-03-31
1.3 M
Rock Springs Capital Management Lp2024-03-31
1.3 M
T. Rowe Price Investment Management,inc.2024-03-31
1.1 M
Logos Global Management Lp2024-03-31
800 K
Hhg Plc2024-03-31
6.1 M
Rtw Investments, Llc2024-03-31
5.4 M
View Akero Therapeutics Diagnostics

Akero Therapeutics Historical Income Statement

At this time, Akero Therapeutics' Reconciled Depreciation is very stable compared to the past year. As of the 14th of July 2024, Non Operating Income Net Other is likely to grow to about 4.7 M, while Selling General Administrative is likely to drop about 16.7 M. View More Fundamentals

Akero Stock Against Markets

Akero Therapeutics Corporate Management

Timothy RolphCoFounder OfficerProfile
Patrick LamySenior StrategyProfile
Catriona YaleExecutive OfficerProfile
William JDCFO, VPProfile
John SchembriVP ControllerProfile

Already Invested in Akero Therapeutics?

The danger of trading Akero Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Akero Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Akero Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Akero Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Information and Resources on Investing in Akero Stock

When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.24)
Return On Assets
(0.20)
Return On Equity
(0.31)
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.